Evidence map›Paper›PMID 31533805›Full record

ArticleArthritis research & therapy2019

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.

Ting-Ting Chung, Kuang-Hui Yu, Chang-Fu Kuo, Shue-Fen Luo, Meng-Jiun Chiou, Wen-Ching Lan, Jung-Sheng Chen, Wen-Yi Tseng, Ao-Ho Hsieh, Lian-Chin Wang

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ting-Ting ChungDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Kuang-Hui YuDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Chang-Fu KuoDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan. zandis@gmail.com.ORCID 0000-0002-9770-5730
Shue-Fen LuoDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Meng-Jiun ChiouDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Wen-Ching LanCenter for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Jung-Sheng ChenDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Wen-Yi TsengDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Ao-Ho HsiehDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Lian-Chin WangDivision of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, No. 5, Fu-Hsing Street, Taoyuan, 333, Taiwan.
Chang Gung Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD).

methodsWe identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012 to 2015. Propensity score (PS)-weighted Cox proportional hazards model was used to estimate hazard ratios (HRs) for CKD progression and improvement. A separate analysis was conducted to assess the HR for CKD progression and CKD recovery among those with worsening CKD.

resultsThe incidence of CKD progression among allopurinol, febuxostat and uricosuric agent users were 1.98, 1.88 and 1.64 per 1000 person-days. Compared with allopurinol users, the PS-weighted HR (95% confidence intervals [CIs]) was 1.77 (0.85-1.76) for febuxostat users and 1.37 (0.71-1.37) for uricosuric agent users for CKD progression and 1.43 (1.26-1.62) for febuxostat users and 1.00 (0.88-1.14) for uricosuric agent users for CKD improvement. Compared to allopurinol users, the HRs for CKD progression were 1.14 (0.80-1.66) for febuxostat users and 0.92 (0.67-1.31) for uricosuric agent users. Among 741 patients who had CKD progression, the incidence of CKD recovery was 1.33, 6.21 and 3.53 per 1000 person-days for allopurinol, febuxostat and uricosuric agent users. The HRs (95% CIs) for recovery in febuxostat and uricosuric agent users were 2.17 (1.40-3.47) and 1.80 (1.20-2.83) compared to allopurinol users.

conclusionsCKD progression and recovery are common in gout patients using ULDs. Febuxostat and benzbromarone were associated with a similar risk of CKD progression with allopurinol, which has a poorer recovery compared with other ULDs.

Indexed as

AllopurinolBenzbromaroneDisease ProgressionFebuxostatFemaleGlomerular Filtration RateGoutGout SuppressantsHumansIncidenceMaleMiddle AgedRecovery of FunctionRenal Insufficiency, ChronicTreatment OutcomeUric AcidAllopurinolBenzbromaroneFebuxostatGout SuppressantsUric AcidUricosuric AgentsAllopurinolChronic kidney diseaseFebuxostatGoutRenal functionUrate-lowering drugUricosuric agents

Identifiers

PMID31533805
PMCPMC6751683
OpenAlexW2973886628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.